IPIX   $0.0175  -2.29% Market Closed

Last Events:

2023-03-30 Trend pattern changed from симметричный треугольник to канал.

2023-03-30 Signal in Stochastic changed from bullish reversal to bearish. The stochastic indicator is in the oversold territory and it falls. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: entry into the oversold zone.

2023-03-30 Signal in MACD changed from bearish weakening to bullish. Oscillator MACD is in the positive territory it's higher than the signal line and grows. These factors mean that positive mood prevails. Last signal: signal line crossed the middle level.

2023-03-30 Signal in RSI changed from bearish weakening to bullish weakening. RSI indicator is in the upper part of the neutral territory and it falls. These factors indicate that the downside trend is confirmed. Last signal: exit from the overbought zone.

2023-03-30 Signal in EMA100 changed from n/a to bearish reversal. 2023-03-22 the price crossed down the moving average line and formed a short-term downside trend.

2023-03-30 Signal in EMA50 changed from bearish reversal to bullish reversal. 2023-03-17 the price crossed up the moving average line and getting closer to the MA, which means that the short-term upside trend weakens.

2023-03-30 Signal in EMA20 changed from n/a to bullish reversal. 2023-03-15 the price crossed up the moving average line and getting closer to the MA, which means that the upside trend weakens.

2023-03-29 Trend pattern changed from канал to симметричный треугольник.


Current temperature: 0.96
ST: 0, Cor:

Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell -
rsi Sell - -
macd - - -
stoch Sell - -
ma20 Sell Sell -
ma50 - - -
ma100 Sell Sell -
Candlestick PatternMarch 2, 2023 Deliberation Block Formation - consists of three black bodies with consecutively lower closes in a downtrend. The final day is a short black candlestick, a spinning top or a doji. Considered to be a bullish reversal pattern.
ISIN US45782D1000
ceo Mr. Leo Ehrlich CPA
Website https://www.ipharminc.com
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.